Guardant Health Launches Guardant Reveal Liquid Biopsy Test for Early-Stage Colorectal Cancer

 Guardant Health Launches Guardant Reveal Liquid Biopsy Test for Early-Stage Colorectal Cancer

Guardant Health Launches Guardant Reveal Liquid Biopsy Test for Early-Stage Colorectal Cancer

Shots:

  • The company has launched Guardant Reveal liquid biopsy test for the detection of residual and recurrent disease from a simple blood draw to monitor CRC patients with 7-day turnaround time, residual disease after surgery and recurrence mos. earlier than current SoC methods like CEA tests or imaging
  • The test can deliver industry leading sensitivity of 91% for detecting ctDNA by simultaneously interrogating both genomic alterations and methylation. Additionally, it reports genomic alterations down to allele frequencies of 0.01%, and effectively filters out biological noise sources
  • The Guardant Reveal test is company’s 1st commercially available liquid biopsy test for clinical use in the management of early-stage cancer which will focus first on early-stage CRC and later on additional cancer types

Click here ­to­ read full press release/ article | Ref: Guardant Health | Image: Guardant Health

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post